Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2020

View Archived Issues

New targets, new booster for CAR-T cells

As nanoparticles, vitamins fight sepsis

Targeting SMPD1 ameliorates leptin resistance-derived endothelial dysfunction in rats

ViiV Healtcare's Dovato receives approval in Japan for HIV infection

Cynata receives approval for its U.K. phase II study in critical limb ischemia

Kannalife presents additional data regarding the MOA of its leading candidate KLS-13019

NantKwest announces phase I data for PD-L1t.haNK

Alexion plans to initiate pivotal phase III CHAMPION-ALS study of Ultomiris in ALS

TROP2-targeted photoimmunotherapy shows promise in preclinical models

Zuclomiphene reduces moderate to severe hot flashes in men with prostate cancer on ADT

TCP-25 wound gel targets wound infection and inflammation in vivo

Cts Biopharma describes new anti-marinobufagenin antibodies

Cugene patents interleukin-2 variants

Kite Pharma discloses vectors encoding recombinant therapeutic T cells receptors

New gemcitabine prodrugs discovered at Shanghai Changchengyiyaokeji

Conatus Pharmaceuticals discovers caspase inhibitors

New STING receptor agonists discovered at Eternity Bioscience

Subtypes take on new importance as KRAS inhibitors proceed

NOTCH3 genetic variant found as a risk factor of stroke

Investigators report ZUMA-2 results with KTE-X19 in mantle cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...